KRAS and colorectal carcinoma: Finally, with the aim of translating these results to real clinical samples, the detection of the KRAS G12V mutation was evaluated in EVs isolated with ExoGAG technology from plasma samples of colorectal cancer (CRC) patients carrying the mutation (previously determined by Beaming technology).